These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 24492307)

  • 1. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.
    Whiteman KR; Johnson HA; Mayo MF; Audette CA; Carrigan CN; LaBelle A; Zukerberg L; Lambert JM; Lutz RJ
    MAbs; 2014; 6(2):556-66. PubMed ID: 24492307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.
    Socinski MA; Kaye FJ; Spigel DR; Kudrik FJ; Ponce S; Ellis PM; Majem M; Lorigan P; Gandhi L; Gutierrez ME; Nepert D; Corral J; Ares LP
    Clin Lung Cancer; 2017 Jan; 18(1):68-76.e2. PubMed ID: 28341109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma.
    Berdeja JG
    Front Biosci (Landmark Ed); 2014 Jan; 19(1):163-70. PubMed ID: 24389179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.
    Wood AC; Maris JM; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Wu J; Kurmasheva RT; Whiteman K; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2013 Nov; 60(11):1860-7. PubMed ID: 23798344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.
    Shah MH; Lorigan P; O'Brien ME; Fossella FV; Moore KN; Bhatia S; Kirby M; Woll PJ
    Invest New Drugs; 2016 Jun; 34(3):290-9. PubMed ID: 26961907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
    Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
    Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Drug Conjugate Targeting c-Kit for the Treatment of Small Cell Lung Cancer.
    Kim KH; Kim JO; Park JY; Seo MD; Park SG
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study.
    Geller JI; Pressey JG; Smith MA; Kudgus RA; Cajaiba M; Reid JM; Hall D; Barkauskas DA; Voss SD; Cho SY; Berg SL; Dome JS; Fox E; Weigel BJ
    Cancer; 2020 Dec; 126(24):5303-5310. PubMed ID: 32914879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
    Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
    Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
    Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer.
    Zhou J; Chen J; Mokotoff M; Zhong R; Shultz LD; Ball ED
    Clin Cancer Res; 2003 Oct; 9(13):4953-60. PubMed ID: 14581370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
    Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
    J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
    Deckert J; Park PU; Chicklas S; Yi Y; Li M; Lai KC; Mayo MF; Carrigan CN; Erickson HK; Pinkas J; Lutz RJ; Chittenden T; Lambert JM
    Blood; 2013 Nov; 122(20):3500-10. PubMed ID: 24002446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
    Tassone P; Gozzini A; Goldmacher V; Shammas MA; Whiteman KR; Carrasco DR; Li C; Allam CK; Venuta S; Anderson KC; Munshi NC
    Cancer Res; 2004 Jul; 64(13):4629-36. PubMed ID: 15231675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in antibody therapeutics targeting small-cell lung cancer.
    Lu H; Jiang Z
    Adv Clin Exp Med; 2018 Sep; 27(9):1317-1323. PubMed ID: 29790694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.
    Weiskopf K; Jahchan NS; Schnorr PJ; Cristea S; Ring AM; Maute RL; Volkmer AK; Volkmer JP; Liu J; Lim JS; Yang D; Seitz G; Nguyen T; Wu D; Jude K; Guerston H; Barkal A; Trapani F; George J; Poirier JT; Gardner EE; Miles LA; de Stanchina E; Lofgren SM; Vogel H; Winslow MM; Dive C; Thomas RK; Rudin CM; van de Rijn M; Majeti R; Garcia KC; Weissman IL; Sage J
    J Clin Invest; 2016 Jul; 126(7):2610-20. PubMed ID: 27294525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
    Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
    Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models.
    Morimura O; Minami T; Kijima T; Koyama S; Otsuka T; Kinehara Y; Osa A; Higashiguchi M; Miyake K; Nagatomo I; Hirata H; Iwahori K; Takimoto T; Takeda Y; Kida H; Kumanogoh A
    Biochem Biophys Res Commun; 2017 Jul; 488(4):596-602. PubMed ID: 28526406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
    Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
    Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer.
    Whalen KA; White BH; Quinn JM; Kriksciukaite K; Alargova R; Au Yeung TP; Bazinet P; Brockman A; DuPont MM; Oller H; Gifford J; Lemelin CA; Lim Soo P; Perino S; Moreau B; Sharma G; Shinde R; Sweryda-Krawiec B; Bilodeau MT; Wooster R
    Mol Cancer Ther; 2019 Nov; 18(11):1926-1936. PubMed ID: 31649014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.